US 8,124,799

Application 12/426,778 · Granted Feb 28, 2012

Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17

Estimated expiration

April 14, 2030

3y 144d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Apr 20, 2009
+ 20 years
Apr 20, 2029
PTA +359d
Apr 14, 2030
No TD
—
Final
Apr 14, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
April 20, 2009
Earliest effective filing
April 20, 2009
Issue date
February 28, 2012
PTA
+359 days
Base expiry (before PTA)
April 20, 2029

April 20, 2009 + 20 years = April 20, 2029 + 359 PTA days = April 14, 2030

  • PRO61/046,342 — Provisional — not used for base term
  • PRO61/111,269 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 1 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 12/426,778 · US 8,124,799

PatentReply compiles the prosecution history behind US 8,124,799: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US8124799

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.